Your browser doesn't support javascript.
loading
Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models.
Funahashi, Yasuhiro; Okamoto, Kiyoshi; Adachi, Yusuke; Semba, Taro; Uesugi, Mai; Ozawa, Yoichi; Tohyama, Osamu; Uehara, Taisuke; Kimura, Takayuki; Watanabe, Hideki; Asano, Makoto; Kawano, Satoshi; Tizon, Xavier; McCracken, Paul J; Matsui, Junji; Aoshima, Ken; Nomoto, Kenichi; Oda, Yoshiya.
Affiliation
  • Funahashi Y; Biomarkers and Personalized Medicine Core Function Unit, Eisai Inc., Andover, Massachusetts, USA.
Cancer Sci ; 105(10): 1334-42, 2014 Oct.
Article in En | MEDLINE | ID: mdl-25060424
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Tubulin Modulators / Tumor Microenvironment / Vascular Remodeling / Furans / Ketones Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Sci Year: 2014 Document type: Article Affiliation country: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Tubulin Modulators / Tumor Microenvironment / Vascular Remodeling / Furans / Ketones Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Cancer Sci Year: 2014 Document type: Article Affiliation country: Estados Unidos